Whether immune checkpoint inhibitors (ICI)—a promising therapeutic approach in lung cancer [9–12]—confer survival benefits in patients with uncommon EGFR mutations or 20ins remained unclear and warranted further investigation. This evidence concerns the gene EGFR and lung cancer.